Literature DB >> 35697384

The Pre-Existing Human Antibody Repertoire to Computationally Optimized Influenza H1 Hemagglutinin Vaccines.

Kaito Nagashima1,2, John V Dzimianski3, Julianna Han4, Nada Abbadi1,2, Aaron D Gingerich2, Fredejah Royer2, Sara O'Rourke3, Giuseppe A Sautto2, Ted M Ross1,2, Andrew B Ward4, Rebecca M DuBois3, Jarrod J Mousa5,2,6.   

Abstract

Computationally optimized broadly reactive Ag (COBRA) hemagglutinin (HA) immunogens have previously been generated for several influenza subtypes to improve vaccine-elicited Ab breadth. As nearly all individuals have pre-existing immunity to influenza viruses, influenza-specific memory B cells will likely be recalled upon COBRA HA vaccination. We determined the epitope specificity and repertoire characteristics of pre-existing human B cells to H1 COBRA HA Ags. Cross-reactivity between wild-type HA and H1 COBRA HA proteins P1, X6, and Y2 were observed for isolated mAbs. The mAbs bound five distinct epitopes on the pandemic A/California/04/2009 HA head and stem domains, and most mAbs had hemagglutination inhibition and neutralizing activity against 2009 pandemic H1 strains. Two head-directed mAbs, CA09-26 and CA09-45, had hemagglutination inhibition and neutralizing activity against a prepandemic H1 strain. One mAb, P1-05, targeted the stem region of H1 HA, but did not compete with a known stem-targeting H1 mAb. We determined that mAb P1-05 recognizes a recently discovered HA epitope, the anchor epitope, and we identified similar mAbs using B cell repertoire sequencing. In addition, the trimerization domain distance from HA was critical to recognition of this epitope by mAb P1-05, suggesting the importance of protein design for vaccine formulations. Overall, these data indicate that seasonally vaccinated individuals possess a population of functional H1 COBRA HA-reactive B cells that target head, central stalk, and anchor epitopes, and they demonstrate the importance of structure-based assessment of subunit protein vaccine candidates to ensure accessibility of optimal protein epitopes.
Copyright © 2022 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35697384      PMCID: PMC9246865          DOI: 10.4049/jimmunol.2101171

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  40 in total

1.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

2.  Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.

Authors:  Donald M Carter; Christopher A Darby; Bradford C Lefoley; Corey J Crevar; Timothy Alefantis; Raymond Oomen; Stephen F Anderson; Tod Strugnell; Guadalupe Cortés-Garcia; Thorsten U Vogel; Mark Parrington; Harold Kleanthous; Ted M Ross
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

3.  cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination.

Authors:  Ali Punjani; John L Rubinstein; David J Fleet; Marcus A Brubaker
Journal:  Nat Methods       Date:  2017-02-06       Impact factor: 28.547

4.  A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus In Vivo.

Authors:  Yael Bar-Peled; Darren Diaz; Alma Pena-Briseno; Jackelyn Murray; Jiachen Huang; Ralph A Tripp; Jarrod J Mousa
Journal:  J Virol       Date:  2019-09-12       Impact factor: 5.103

5.  A Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against Hemagglutinin.

Authors:  Giuseppe A Sautto; Greg A Kirchenbaum; Rodrigo B Abreu; Jeffrey W Ecker; Spencer R Pierce; Harry Kleanthous; Ted M Ross
Journal:  J Immunol       Date:  2019-12-06       Impact factor: 5.422

Review 6.  Continuing challenges in influenza.

Authors:  Robert G Webster; Elena A Govorkova
Journal:  Ann N Y Acad Sci       Date:  2014-05-30       Impact factor: 5.691

7.  First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes.

Authors:  Jenna J Guthmiller; Julianna Han; Lei Li; Alec W Freyn; Sean T H Liu; Olivia Stovicek; Christopher T Stamper; Haley L Dugan; Micah E Tepora; Henry A Utset; Dalia J Bitar; Natalie J Hamel; Siriruk Changrob; Nai-Ying Zheng; Min Huang; Florian Krammer; Raffael Nachbagauer; Peter Palese; Andrew B Ward; Patrick C Wilson
Journal:  Sci Transl Med       Date:  2021-06-02       Impact factor: 17.956

8.  Development of a Pan-H1 Influenza Vaccine.

Authors:  Nicole Darricarrère; Svetlana Pougatcheva; Xiaochu Duan; Rebecca S Rudicell; Te-Hui Chou; Joshua DiNapoli; Ted M Ross; Tim Alefantis; Thorsten U Vogel; Harry Kleanthous; Chih-Jen Wei; Gary J Nabel
Journal:  J Virol       Date:  2018-10-29       Impact factor: 5.103

9.  Broadly neutralizing antibodies target a haemagglutinin anchor epitope.

Authors:  Jenna J Guthmiller; Julianna Han; Henry A Utset; Lei Li; Linda Yu-Ling Lan; Carole Henry; Christopher T Stamper; Meagan McMahon; George O'Dell; Monica L Fernández-Quintero; Alec W Freyn; Fatima Amanat; Olivia Stovicek; Lauren Gentles; Sara T Richey; Alba Torrents de la Peña; Victoria Rosado; Haley L Dugan; Nai-Ying Zheng; Micah E Tepora; Dalia J Bitar; Siriruk Changrob; Shirin Strohmeier; Min Huang; Adolfo García-Sastre; Klaus R Liedl; Jesse D Bloom; Raffael Nachbagauer; Peter Palese; Florian Krammer; Lynda Coughlan; Andrew B Ward; Patrick C Wilson
Journal:  Nature       Date:  2021-12-23       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.